欢迎登录材料期刊网

材料期刊网

中国科学院金属研究所 科学出版社
高级检索
  1. 首页
  2. 期刊
  3. 稀土
  4. 碳酸镧在高磷血症中的应用

稀土, 2011, 32(1): 75-79. doi: 10.3969/j.issn.1004-0277.2011.01.017

碳酸镧在高磷血症中的应用

邵海丽 1, , 柳召刚 2, , 李梅 3, , 吴锦绣 4, , 胡艳宏 5,

1.内蒙古科技大学,材料与冶金学院,内蒙古自治区高校稀土现代冶金新技术与应用重点实验室,内蒙古,包头,014010

2.内蒙古科技大学,材料与冶金学院,内蒙古自治区高校稀土现代冶金新技术与应用重点实验室,内蒙古,包头,014010

3.内蒙古科技大学,材料与冶金学院,内蒙古自治区高校稀土现代冶金新技术与应用重点实验室,内蒙古,包头,014010

4.内蒙古科技大学,材料与冶金学院,内蒙古自治区高校稀土现代冶金新技术与应用重点实验室,内蒙古,包头,014010

5.内蒙古科技大学,材料与冶金学院,内蒙古自治区高校稀土现代冶金新技术与应用重点实验室,内蒙古,包头,014010

基金项目:   国家自然科学基金(20966007)   内蒙古自治区自然科学基金重大项目(20080404ZD10)  

关键词： 高磷血症 , 慢性肾衰竭 , 磷酸盐 , 磷结合剂 , 碳酸镧

Application of Lanthanum Carbonate in Hyperphosphataemia Treatment

镧制剂能有效降低血清中磷的含量,而且不会引起肾性骨病和高钙血症,其有效性和安全性较好,是新型的磷结合剂.本文将重点介绍临床应用较多的镧制剂-碳酸镧.

参考文献

[1] 王海燕;王梅.慢性肾脏病及透析的临床指南[M].北京:人民卫生出版社,2004:141-153.
[2] Martin KJ;Gonzalez EA .Strategies to minimize bone disease in renal failure.[J].American Journal of Kidney Diseases,2001(6):1430-1436.
[3] Block,GA;Port,FK .Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management.[J].American Journal of Kidney Diseases,2000(6):1226-1237.
[4] Goodman WG;Goldin J;Kuizon BD;Yoon C;Gales B;Sider D;Wang Y;Chung J;Emerick A;Greaser L;Elashoff RM;Salusky IB .Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis.[J].The New England journal of medicine,2000(20):1478-1483.
[5] Shigematsu T;Kono T;Satoh K;Yokoyama K;Yoshida T;Hosoya T;Shirai K .Phosphate overload accelerates vascular calcium deposition in end-stage renal disease patients.[J].Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association,2003(Suppl.3610):iii86-89.
[6] Ganesh SK;Stack AG;Levin NW;Hulbert-Shearon T;Port FK .Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients.[J].Journal of the American Society of Nephrology: JASN,2001(10):2131-2138.
[7] Kestenbaum B;Sampson J N;Rudser K D et al.Serum phosphate levels and mortality risk among people with chronic kidney disease[J].Journal of the American Society of Nephrology,2005,16:520-528.
[8] Spasovski GB .Bone health and vascular calcification relationships in chronic kidney disease.[J].International Urology and Nephrology,2007(4):1209-1216.
[9] Hutchison A J;Barnett ME;Kwan JTC et al.Long-Term Efficacy and Safety Profile of Lanthanum Carbonate:Results for Up to 6 Years of Treatment.Nephron[J].Clin Practice,2008,110(01):c15-c23.
[10] Block G A;Hulbert-Shearon TE;Lebin NW et al.Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients:A national study[J].American Journal of Kidney Diseases,1998,31:607-617.
[11] 李洪清,刘会龙,孙宝玉.慢性肾衰竭患者高磷血症的防治[J].实用诊断与治疗杂志,2007(07):559-560.
[12] 王世相,管德林.血液透析患者高磷血症的治疗进展[J].中国血液净化,2003(02):93-96.
[13] Clarkson E M;Luck V A;Hymson W V et al.The effect of aluminium hydroxide on calcium,phosphorus and aluminium balances,the serumparathyroid hormone concentration and the aluminium content of bone in patients with chronic renal failure[J].Clinical Science,1972,43:519-531.
[14] Slaopolsky E;Delmez J A .Pathogensis of secondary hy-Perparathyroidism[J].American Journal of Kidney Diseases,1994,23:229-236.
[15] Locatelli F;Cannata Andia JB;Drueke TB;Horl WH;Fouque D;Heimburger O;Ritz E .Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia.[J].Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association,2002(5):723-731.
[16] Norris K C;Crooks P W;Nebeker H G et al.Clinical and laboratory features of aluminum-related bone disease:Differences sporadic and"epidemic"forms of the syndrome[J].American Journal of Kidney Diseases,1985,6(05):342-347.
[17] Emmett M;Sirmon M D;Kirkpatrick W G et al.Calcium acetate control of serum phosphorus in hemodialysis patients[J].American Journal of Kidney Diseases,1991,17:544-550.
[18] Almirall J;Campistol J M;Torras A et al.Calcium carbonate as phosphate binder in dialysis[J].The Lancet,1987,2:799-800.
[19] 潘明明,苗华.高磷血症治疗新进展[J].国际移植与血液净化杂志,2006(06):12-14.
[20] 杨剑辉,孟建中.新型磷酸盐结合剂萨佛拉莫[J].国外医学（泌尿系统分册）,2005(03):340-343.
[21] Chertow G M;Borke S K;Lazarus J M et al.Poly[al-Lylamine hydrochloride](RenaGel):a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure[J].American Journal of Kidney Diseases,1997,29:66-71.
[22] Goldsmith DR;Scott LJ;Cvetkovic RS;Plosker GL .Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis.[J].Drugs: International Journal of Current Therapeutics and Applied Pharmacology Reviews, Featuring Evaluations on New Drugs, Review Articles on Drugs and Drug Therapy, and Drug Literature Abstracts,2008(1):85-104.
[23] Brennan A;Wilson R;Davis S et al.Economic evaluation of the use of lanthanum carbonate from an Anstral-Ian perspective[J].Nephrology Dialysis Transplantation,2007,22:186.
[24] 张金超,杨梦苏.稀土配合物药物研究进展[J].稀有金属,2005(06):919-926.
[25] 杨军,张赫,王甲辰,刘向生,伍艳平,赵凤红.稀土抑菌作用研究[J].稀土,2009(01):35-39.
[26] 吴锦绣,李梅,柳召刚,胡艳宏.荧光法研究稀土与血清白蛋白相互作用的进展[J].稀土,2009(02):86-90.
[27] Damment S J P;Totten W.The parmacology of a newphosphate binder,lanthanum carbonate[A].Berlin,Germany,2003
[28] Albaaj F;Hutchison A .Hyperphosphataemia in renal failure : causes, consequences and current management.[J].Drugs: International Journal of Current Therapeutics and Applied Pharmacology Reviews, Featuring Evaluations on New Drugs, Review Articles on Drugs and Drug Therapy, and Drug Literature Abstracts,2003(6):577-596.
[29] 谢单丹.高磷酸盐血症治疗药碳酸镧（Ianthanum carbonate）[J].世界临床药物,2007(12):761-762.
[30] Damment SJ;Cox AG;Secker R .Dietary administration in rodent studies distorts the tissue deposition profile of lanthanum carbonate; brain deposition is a contamination artefact?[J].Toxicology Letters,2009(3):223-229.
[31] Neven E;Dams G;Postnov A .Adequate phosphate binding with lanthanum carbonate attenuates arterial calcification in chronic renal failure rats.[J].Nephrology, dialysis, transplantation,2009(6):1790-1799.
[32] Damment S J P;Pennick M .Systemic lanthanum is excreted in the bile of rats[J].Toxicology Letters,2007,171(1-2):69-77.
[33] Persy VP;Behets GJ;Bervoets AR;De Broe ME;D'Haese PC .Lanthanum: a safe phosphate binder.[J].Seminars in dialysis,2006(3):195-199.
[34] Steve Damment .Influence Of Bile Acids On The Phosphate-Binding Efficacy Of Lanthanum Carbonate And Sevelamer Hydrochloride[N].ASN poster,2005.
[35] Grassman A;Gioberge S;Moeller S;Brown G .ESRD patients in 2004:global overview of patient numbers,treatment modalities and associated trends[J].Nephrology Dialysis Transplantation,2005,20:2587-2593.
[36] D' Hease P C;Spasovski G B;Sikole A et al.A multicenter study on the effects of lanthanum carbonate and calcium carbonateon renal bone diasease in dialysis patients[J].Kidney International,2003,63:73-78.
[37] Alastair J;Hutchison;Maurice Laville .Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden[J].Nephrology Dialysis Transplantation,2008,23:3677-3684.
[38] Neven E;Dams G;Postnov A .Adequate phosphate binding with lanthanum carbonate attenuates arterial calcification in chronic renal failure rats.[J].Nephrology, dialysis, transplantation,2009(6):1790-1799.
[39] Damment SJ;Pennick M .Clinical pharmacokinetics of the phosphate binder lanthanum carbonate.[J].Clinical pharmacokinetics,2008(9):553-563.
[40] Pratt R;Smyth M .Effective reduction of serum phosphorus using lanthanum carbonate,with fewer tablets than sevelamer hydrochloride[J].Nephrology Dialysis Transplantation,2007,22:176-183.
[41] A.J. Hutchison;B. Maes;J. Vanwalleghem;G. Asmus;E. Mohamed;R. Schmieder .Efficacy, Tolerability, and Safety of Lanthanum Carbonate in Hyperphosphatemia: A 6-month, Randomized, Comparative Trial versus Calcium Carbonate[J].Nephron,2005(1):c8-c19.
[42] Finn WF .Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients.[J].Clinical nephrology,2006(3):191-202.
[43] Bronner F;Slepchenko BM;Pennick M;Damment SJ .A Model of the Kinetics of Lanthanum in Human Bone, Using Data Collected during the Clinical Development of the Phosphate Binder Lanthanum Carbonate.[J].Clinical pharmacokinetics,2008(8):543-552.
上一张 下一张
上一张 下一张
计量
  • 下载量()
  • 访问量()
作者相关
文章评分
  • 您的评分：
  • 1
    0%
  • 2
    0%
  • 3
    0%
  • 4
    0%
  • 5
    0%

版权所有©2010中国科学院金属研究所中国科技出版传媒股份有限公司

本系统由北京仁和汇智信息技术有限公司设计开发

技术支持：info@rhhz.net